ArticleNature cancer2025
MCSP
Abstract read
In one paragraph
Article in Nature cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Role of Extracellular Vesicles in Shaping Immune Responses in the Lymph Node Microenvironment.Biology of the cell · 2026Review
- Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma.Journal of translational medicine · 2026Article
- Melanoma evolution in the lymph node shapes systemic outcomes.bioRxiv : the preprint server for biology · 2026Article
- The sleeping threat: targeting cancer dormancy to transform metastasis therapy.Nature reviews. Cancer · 2026Review
- High-Dimensional Immunophenotyping of Plasma-Derived Small Extracellular Vesicles in Pancreatic Cancer: An Exploratory Proof-of-Principle Study.Biomolecules · 2026Article
- Protocol for validating drug efficacy and safety in scalable 96-well platforms of human cortical organoids and melanoma brain metastases.STAR protocols · 2026Article
- Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy.Journal for immunotherapy of cancer · 2026Article
- Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.Nature reviews. Clinical oncology · 2026Review
- Oncofetal chondroitin sulfate positive circulating tumor cells as prognostic biomarkers in early-stage melanoma.Scientific reports · 2026Article
- Exploration of the Immune Microenvironment of Melanoma and Construction of Prognostic Models Based on the Expression Profile of Lysine Crotonylation-Related Genes.International journal of general medicine · 2026Article
- Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients.EMBO molecular medicine · 2026Article
- Cortical organoid-derived models of the melanoma brain metastatic niche enable prioritization of cancer-targeting drugs.Cell reports methods · 2025Article
- Fishing for melanoma metastasis-initiating cells in lymph nodes.Nature cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Severin Guetter *Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0001-8253-3609
Courtney König *Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Huiqin Koerkel-Qu *Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Aleksandra MarkiewiczExperimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0003-4590-4698
Sebastian ScheitlerExperimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Marie KatzerDepartment of Dermatology, University Medical Center Regensburg, Regensburg, Germany.
Mark BerneburgDepartment of Dermatology, University Medical Center Regensburg, Regensburg, Germany.
Philipp RennerDepartment of Surgery, University Medical Center Regensburg, Regensburg, Germany.
Beatrix CucuruzDepartment of Vascular Surgery, University Medical Center Regensburg, Regensburg, Germany.
Leonhard GuttenbergerExperimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Veronika NaimerExperimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Kathrin WeideleDivision of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany.ORCID http://orcid.org/0009-0008-9313-5057
Steffi TreitschkeDivision of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany.
Christian WernoDivision of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany.
Hanna JaserExperimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Tonia BargmannPreclinical Pharmacology and Toxicology, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM member of Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH) in the German Center for Lung Research (DZL), Hannover, Germany.ORCID http://orcid.org/0000-0002-5170-4687
Armin BraunPreclinical Pharmacology and Toxicology, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM member of Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH) in the German Center for Lung Research (DZL), Hannover, Germany.
Florian WeberInstitute of Pathology, University of Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0001-7480-8828
Katja EvertInstitute of Pathology, University of Regensburg, Regensburg, Germany.
Alexander RochwargerDepartment of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.
Christian M SchürchDepartment of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-1792-1768
Katharina LimmInstitute of Functional Genomics, University of Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0001-9785-2338
Peter J OefnerInstitute of Functional Genomics, University of Regensburg, Regensburg, Germany.
Reinhard RachelCenter for Electron Microscopy, University of Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0001-6367-1221
Felix BaumannDepartment of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany.
Jens WarfsmannDivision of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany.
Lisa SchmidleithnerLeibniz Institute for Immunotherapy, University Hospital Regensburg, Regensburg, Germany.
Kathrin GuetterLeibniz Institute for Immunotherapy, University Hospital Regensburg, Regensburg, Germany.
Parvaneh MohammadiExperimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Anja UlmerDepartment of Dermatology, University of Tübingen, Tübingen, Germany.
Sebastian HaferkampDepartment of Dermatology, University Medical Center Regensburg, Regensburg, Germany.
Christoph A Klein *Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. christoph.klein@ukr.de.ORCID http://orcid.org/0000-0001-7128-1725
Melanie Werner-Klein *Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. melanie.werner-klein@ukr.de.ORCID http://orcid.org/0000-0002-5677-9346
Funding
Deutsche Forschungsgemeinschaft (German Research Foundation) B09 FOR2127Deutsche Forschungsgemeinschaft (German Research Foundation) B09/TRR 305Deutsche Forschungsgemeinschaft (German Research Foundation) B13/TRR 305Deutsche Forschungsgemeinschaft (German Research Foundation) KL1233/10-2Deutsche Forschungsgemeinschaft (German Research Foundation) KL1233/11-2Deutsche Forschungsgemeinschaft (German Research Foundation) KL1233/14-1Deutsche Forschungsgemeinschaft (German Research Foundation) WE 4632/5-1/Deutsche Forschungsgemeinschaft (German Research Foundation) Z02/TRR 305Deutsche Krebshilfe (German Cancer Aid) 70112463EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) CAR-TIME, 101116768EC | European Regional Development Fund (Europski Fond za Regionalni Razvoj) INTERREG BY/CZ-118Wilhelm Sander-Stiftung (Wilhelm Sander Foundation) 2015.016.1
Abstract
To investigate the early, poorly understood events driving metastatic progression, we searched for the earliest detectable disseminated cancer cells (DCCs), also often referred to as disseminated tumor cells (DTCs), in sentinel lymph node (SLN) biopsies of 492 patients with stage I-III melanoma. Using micromanipulator-assisted isolation of rare DCCs, single-cell mRNA and DNA sequencing, codetection by indexing immunofluorescence imaging and survival analysis, we identified melanoma-associated chondroitin sulfate proteoglycan (MCSP)
Indexed as
Chondroitin Sulfate ProteoglycansMelanomaSkin NeoplasmsCD8-Positive T-LymphocytesFemaleHumansImmune ToleranceLymphatic MetastasisMaleSentinel Lymph NodeSentinel Lymph Node BiopsyTumor EscapeChondroitin Sulfate Proteoglycans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.